Shandong Bailong Chuangyuan Bio-Tech Balance Sheet Health
Financial Health criteria checks 6/6
Shandong Bailong Chuangyuan Bio-Tech has a total shareholder equity of CN¥1.6B and total debt of CN¥70.0M, which brings its debt-to-equity ratio to 4.3%. Its total assets and total liabilities are CN¥1.9B and CN¥306.3M respectively. Shandong Bailong Chuangyuan Bio-Tech's EBIT is CN¥227.8M making its interest coverage ratio -42.4. It has cash and short-term investments of CN¥408.7M.
Key information
4.3%
Debt to equity ratio
CN¥70.00m
Debt
| Interest coverage ratio | -42.4x |
| Cash | CN¥408.66m |
| Equity | CN¥1.62b |
| Total liabilities | CN¥306.30m |
| Total assets | CN¥1.93b |
Recent financial health updates
No updates
Recent updates
Shandong Bailong Chuangyuan Bio-Tech's (SHSE:605016) Solid Profits Have Weak Fundamentals
Nov 06
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.'s (SHSE:605016) Intrinsic Value Is Potentially 78% Above Its Share Price
Oct 14Many Still Looking Away From Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (SHSE:605016)
Sep 29Here's Why Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Has Caught The Eye Of Investors
Aug 23Returns On Capital At Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Have Hit The Brakes
Jun 26Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (SHSE:605016) Analysts Are More Bearish Than They Used To Be
May 06Concerns Surrounding Shandong Bailong Chuangyuan Bio-Tech's (SHSE:605016) Performance
May 03If EPS Growth Is Important To You, Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Presents An Opportunity
Mar 27Financial Position Analysis
Short Term Liabilities: 605016's short term assets (CN¥856.6M) exceed its short term liabilities (CN¥301.4M).
Long Term Liabilities: 605016's short term assets (CN¥856.6M) exceed its long term liabilities (CN¥4.9M).
Debt to Equity History and Analysis
Debt Level: 605016 has more cash than its total debt.
Reducing Debt: 605016's debt to equity ratio has reduced from 9.5% to 4.3% over the past 5 years.
Debt Coverage: 605016's debt is well covered by operating cash flow (310.5%).
Interest Coverage: 605016 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:46 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xia Sheng | Citic Securities Co., Ltd. |
| Lin Yang | Guosen Securities Co., Ltd. |
| Wei Liu | Haitong International Research Limited |